PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022

Description:

PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022

Summary

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain. GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Similar to the situation in the UK, sales in the Japanese market are severely constrained by the absence of a routine HBV immunization program. Furthermore, Japan also does not target adult risk groups for HBV immunization, an approach that is unique among the eight markets discussed in this report. While Japanese policymakers have hinted at a more pro-vaccine stance, GlobalData does not expect HBV immunization recommendations to be expanded in Japan during the forecast period, which poses a serious barrier to market growth.

Scope

- Overview of Hepatitis B disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Hepatitis B disease market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis B disease
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Japan

Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Overview
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.3 Symptoms
3.4 Prognosis
4 Vaccination Recommendations and Coverage Rates
4.1 Overview
4.2 Japan
4.2.1 Immunization Recommendations and Policies
4.2.2 Vaccination Coverage
4.2.3 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Monovalent Vaccines
5.3.1 Recombivax HB
5.3.2 Birmugen
5.4 Product Profiles - Combination Vaccines
6 Opportunity and Unmet Need
6.1 Overview
6.2 Increased Vaccine Immunogenicity
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Increased Vaccination Coverage Rates
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity
6.4 Increased Patient Awareness
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.4.3 Opportunity
6.5 Improved Physician Education
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.5.3 Opportunity
6.6 More Cost-Effective Vaccines
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.6.3 Opportunity
7 Market Outlook
7.1 Japan
7.1.1 Forecast
7.1.2 Drivers and Barriers
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 Forecasting Methodology
8.4.1 Patient Populations Targeted for Vaccination
8.4.2 Vaccination Coverage Rates
8.4.3 Vaccinated Patients
8.4.4 Regulatory Approval vs. Advisory Committee Recommendation
8.4.5 Vaccines Included
8.4.6 Key Launch Dates
8.4.7 General Pricing Assumptions
8.4.8 Individual Vaccine Assumptions
8.5 Physicians and Specialists Included in this Study
8.5.1 Interviews of Key Opinion Leaders (KOLs)
8.5.2 Online Survey of High-Prescribing Physicians (non-KOLs)
8.6 About the Authors
8.6.1 Analyst
8.6.2 Therapy Area Director
8.6.3 Global Head of Healthcare
8.7 About Us
8.8 Disclaimer

1.1 List of Tables
Table 1: Modes of HBV Transmission
Table 2: HBV Serological Markers and Test Interpretations
Table 3: Symptoms of HBV Infection
Table 4: HBV Vaccination Advisory Committees by Country
Table 5: HBV Immunization Recommendations by Country
Table 6: Targeted Age Group(s) for Routine Immunization and Most Administered HBV Vaccines by Country
in the Global Markets, 2014
Table 7: Leading Vaccines for HBV, 2014
Table 8: Product Profile - Recombivax HB
Table 9: Immunogenicity Profile - Recombivax HB
Table 10: Safety Profile - Recombivax HB
Table 11: Recombivax HB SWOT Analysis, 2014
Table 12: Product Profile - Bimmugen
Table 13: Bimmugen SWOT Analysis, 2014
Table 14: Unmet Need and Opportunity in Prophylactic HBV Vaccines
Table 15: Sales Forecasts ($) for HBV Vaccines in Japan, 2012-2022
Table 16: Japan HBV Vaccine Market - Drivers and Barriers, 2014
Table 17: Patient Population(s) Targeted for HBV Vaccination in the Pediatric Market, Japan
Table 18: Key Launch Dates
Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, Japan

1.2 List of Figures
Figure 1: HBV Structure and the Recombinant Vaccine Development Process
Figure 2: High-Prescriber Estimation of Pediatric HBV Vaccine Patient Share in Japan, 2014
Figure 3: Sales for HBV Vaccines in Japan, 2012-2022

Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit 
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022
Web Address: http://www.researchandmarkets.com/reports/2785107/
Office Code: SC6I6YY8

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 4995</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 9990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 14985</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: __________________________________________ Last Name: _______________________________________
Email Address: * _______________________________________
Job Title: __________________________________________
Organisation: ________________________________________
Address: __________________________________________
City: _______________________________________________
Postal / Zip Code: ___________________________________
Country: __________________________________________
Phone Number: ______________________________________
Fax Number: ________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World